1. Home
  2. FMST vs RNTX Comparison

FMST vs RNTX Comparison

Compare FMST & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FMST
  • RNTX
  • Stock Information
  • Founded
  • FMST 2005
  • RNTX 2001
  • Country
  • FMST Canada
  • RNTX United States
  • Employees
  • FMST N/A
  • RNTX N/A
  • Industry
  • FMST Other Metals and Minerals
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FMST Basic Materials
  • RNTX Health Care
  • Exchange
  • FMST Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • FMST 38.2M
  • RNTX 34.6M
  • IPO Year
  • FMST N/A
  • RNTX N/A
  • Fundamental
  • Price
  • FMST $3.95
  • RNTX $1.25
  • Analyst Decision
  • FMST
  • RNTX Buy
  • Analyst Count
  • FMST 0
  • RNTX 2
  • Target Price
  • FMST N/A
  • RNTX $10.00
  • AVG Volume (30 Days)
  • FMST 748.1K
  • RNTX 214.3K
  • Earning Date
  • FMST 11-21-2025
  • RNTX 11-13-2025
  • Dividend Yield
  • FMST N/A
  • RNTX N/A
  • EPS Growth
  • FMST N/A
  • RNTX N/A
  • EPS
  • FMST N/A
  • RNTX N/A
  • Revenue
  • FMST N/A
  • RNTX N/A
  • Revenue This Year
  • FMST N/A
  • RNTX N/A
  • Revenue Next Year
  • FMST N/A
  • RNTX N/A
  • P/E Ratio
  • FMST N/A
  • RNTX N/A
  • Revenue Growth
  • FMST N/A
  • RNTX N/A
  • 52 Week Low
  • FMST $0.55
  • RNTX $1.04
  • 52 Week High
  • FMST $5.74
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • FMST 59.40
  • RNTX 49.42
  • Support Level
  • FMST $3.43
  • RNTX $1.18
  • Resistance Level
  • FMST $4.57
  • RNTX $1.44
  • Average True Range (ATR)
  • FMST 0.39
  • RNTX 0.09
  • MACD
  • FMST 0.05
  • RNTX -0.00
  • Stochastic Oscillator
  • FMST 62.84
  • RNTX 23.81

About FMST Foremost Lithium Resource & Technology Ltd. Common stock

Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: